123 related articles for article (PubMed ID: 38669521)
1. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.
Kimura N; Tsukita Y; Ebina-Shibuya R; Miyauchi E; Yamada M; Narita D; Saito R; Inoue C; Fujino N; Ichikawa T; Tamada T; Sugiura H
Cancer Biomark; 2024 Mar; ():. PubMed ID: 38669521
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
6. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
[TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
8. Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer.
Hu Y; Li S; Xiao H; Xiong Y; Lu X; Yang X; Luo W; Luo J; Zhang S; Cheng Y; Zhang L; Dai X; Yang Y; Wang D; Li M
Cancer Med; 2023 Jun; 12(11):12234-12252. PubMed ID: 37062076
[TBL] [Abstract][Full Text] [Related]
9. Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance.
Zhou J; Chu X; Zhao J; Xie M; Wu J; Yu X; Fang Y; Li Y; Li X; Su C
Biol Proced Online; 2023 Jul; 25(1):21. PubMed ID: 37488517
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
11. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
12. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.
Iso H; Hisakane K; Mikami E; Suzuki T; Matsuki S; Atsumi K; Nagata K; Seike M; Hirose T
Transl Lung Cancer Res; 2023 Sep; 12(9):1850-1861. PubMed ID: 37854151
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
[TBL] [Abstract][Full Text] [Related]
14. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With
Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y
JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645
[TBL] [Abstract][Full Text] [Related]
16. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
17. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
18. Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression.
Ding K; Yi M; Liang H; Li Z; Zhang Y
Expert Rev Clin Immunol; 2022 Jul; 18(7):759-771. PubMed ID: 35681264
[TBL] [Abstract][Full Text] [Related]
19. Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.
Tenuta M; Pandozzi C; Sciarra F; Campolo F; Gelibter AJ; Sirgiovanni G; Cortesi E; Lenzi A; Isidori AM; Sbardella E; Venneri MA
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509255
[TBL] [Abstract][Full Text] [Related]
20. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.
Zhang P; Ma M; Nie J; Dai L; Hu W; Zhang J; Wu D; Chen X; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Hao Q; Fang J
Heliyon; 2024 Feb; 10(4):e26026. PubMed ID: 38390071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]